UPCDC-30245 is an allosteric p97 inhibitor with an IC 50 of approximately 27 nM UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC 50 =300 nM) and shows 3-fold resistance for p97 mutant T688A . UPCDC-30245 can be used in the research of cancer In Vitro UPCDC-30245 binds at the junction between the D1 dan D2 domains of p97. UPCDC-30245 inhibits cell proliferation in HeLa, A549, BxPC-3, PRMI8226, MM1S, HCT116 cells, and appears more potent in HT29 cells. UPCDC-30245 (0.01-100 μM) shows anti-proliferative effects on parental and CB-5083 resistant HCT116 cell lines that harbor a new p97 double mutation (D649A/T688A). UPCDC-30245 (4 μm; 2, 6, 10, 18, 24 hours; functional enrichment analysis) is not linked to pathways typically impacted by p97 inhibition, such as protein processing in the ER, UPR, and asparagine N-linked glycosylation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:allosteric p97|27 nM (IC|50|)|wild type p97|300 nM (IC|50|)